Drugs

Over-The-Counter Drugs Exhibit a Spike in Demand Worldwide as Hospitals Become Overstretched - ResearchAndMarkets.com

Monday, April 6, 2020 - 10:00pm

DUBLIN, April 6, 2020 /PRNewswire/ -- ResearchAndMarkets.com identifies Over-the-counter Drugs as one of the key industries seeing increased demand due to the coronavirus pandemic.

Key Points: 
  • DUBLIN, April 6, 2020 /PRNewswire/ -- ResearchAndMarkets.com identifies Over-the-counter Drugs as one of the key industries seeing increased demand due to the coronavirus pandemic.
  • With hospitals overstretched by the crisis and mild cases of COVID-19 treatable with paracetamol and other common drugs, pharmacies and other retailers will have to keep well stocked.
  • Also, other health problems don't stop for a pandemic, and people have all the same diseases they would ordinarily have, with the same demand for pharmaceuticals.
  • Latest available reports on this sector include:

MedinCell Has Launched a COVID-19 Research Initiative Based on Its Experience to Formulate Long-Acting Injectable Ivermectin

Monday, April 6, 2020 - 6:41pm

Ivermectin has a long track record of use as a safe and effective drug to treat several parasitic diseases.

Key Points: 
  • Ivermectin has a long track record of use as a safe and effective drug to treat several parasitic diseases.
  • MedinCell has launched a few weeks ago a research initiative on a long-acting injectable formulation of Ivermectin and believes it could have a role to play in Covid-19 management.
  • In case of positive results, a BEPO technology based long-acting injectable Ivermectin offers a rapidly deployable and affordable solution for a global pandemic.
  • Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.

Over-The-Counter Drugs Experience Surge in Demand due to Spread of COVID-19 - ResearchAndMarkets.com

Monday, April 6, 2020 - 5:32pm

ResearchAndMarkets.com identifies Over-the-counter Drugs as one of the key industries seeing increased demand due to the Coronavirus pandemic.

Key Points: 
  • ResearchAndMarkets.com identifies Over-the-counter Drugs as one of the key industries seeing increased demand due to the Coronavirus pandemic.
  • With hospitals overstretched by the crisis and mild cases of COVID-19 treatable with paracetamol and other common drugs, pharmacies and other retailers will have to keep well stocked.
  • Also, other health problems dont stop for a pandemic, and people have all the same diseases they would ordinarily have, with the same demand for pharmaceuticals.
  • Latest available reports on this sector include:

Perrigo Announces FDA Approval for the Store Brand Equivalent of Voltaren® Arthritis Pain

Monday, April 6, 2020 - 1:30pm

On February 14, 2020, the FDA approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1%) for nonprescription or OTC, use through its prescription (Rx)-to-OTC switch process.

Key Points: 
  • On February 14, 2020, the FDA approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1%) for nonprescription or OTC, use through its prescription (Rx)-to-OTC switch process.
  • The product will be marketed under retailer's store brand labels and will provide consumers with a high-quality, value alternative to GSK's Voltaren Arthritis Pain, which is indicated for the temporary relief of arthritis pain.
  • Perrigo President and CEO Murray S. Kessler commented, "This product approval and upcoming launch demonstrates the power and versatility of Perrigo's OTC self-care platform.
  • Our ability to successfully drive Rx-to-OTC switches differentiates Perrigo in the market place and is a perfect example of the Perrigo Advantage."

GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That EPIDIOLEX® (cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance

Monday, April 6, 2020 - 2:00pm

Following FDA approval, EPIDIOLEX was initially placed in Schedule V of the CSA.

Key Points: 
  • Following FDA approval, EPIDIOLEX was initially placed in Schedule V of the CSA.
  • Following receipt of this DEA notification, GW has filed a post-approval supplement with FDA to remove Schedule V designation from EPIDIOLEX.
  • The Company will now begin the process of implementing these changes at the state level and through the EPIDIOLEX distribution network.
  • The medicine is marketed in the United States by Greenwich Biosciences, the U.S. subsidiary of GW Pharmaceuticals plc.

REPEAT/Halo Announces Proposed Acquisition of Nasalbinoid Natural Devices and Concurrent Private Placement

Monday, April 6, 2020 - 1:30pm

The common shares issued by Halo in conjunction with the planned acquisition will be subject to certain sale restrictions.

Key Points: 
  • The common shares issued by Halo in conjunction with the planned acquisition will be subject to certain sale restrictions.
  • Nasalbinoids personal nasal inhalers are infused with natural scents to provide a convenient refreshing dose of CBD aromatherapy.
  • NND has a line of three unique refillable inhalers and proprietary formulations: Tropical, Berry and Cinnamint, with more in development.
  • The forward-looking information and forward-looking statements contained herein may include, but is not limited to, statements regarding the acquisition of Nasalbinoid Natural Devices, the concurrent private placement, and the finders fee.

IMMUNOMEDICS ANNOUNCES ASCENT STUDY TO BE STOPPED FOR COMPELLING EFFICACY

Monday, April 6, 2020 - 1:00pm

This decision was based on the unanimous recommendation by the independent Data Safety Monitoring Committee (DSMC), during its recent routine review of the ASCENT study.

Key Points: 
  • This decision was based on the unanimous recommendation by the independent Data Safety Monitoring Committee (DSMC), during its recent routine review of the ASCENT study.
  • I look forward to the release of the full and final analyses of these study data when they are available for public presentation.
  • ASCENT is a Phase 3 confirmatory study designed to validate the promising safety and efficacy data of sacituzumab govitecan observed in a Phase 2 study of heavily pretreated patients with metastatic TNBC (mTNBC).
  • We are grateful to all the patients, their families and healthcare providers who participated in the ASCENT study.

Halo Announces Proposed Acquisition of Nasalbinoid Natural Devices and Concurrent Private Placement

Saturday, April 4, 2020 - 4:23am

The common shares issued by Halo in conjunction with the planned acquisition will be subject to certain sale restrictions.

Key Points: 
  • The common shares issued by Halo in conjunction with the planned acquisition will be subject to certain sale restrictions.
  • Nasalbinoids personal nasal inhalers are infused with natural scents to provide a convenient refreshing dose of CBD aromatherapy.
  • As a condition to closing the Acquisition, Halo is pleased to announce a concurrent non-brokered private placement of Halo common shares at a price of C$0.11 per share for aggregate gross proceeds of up to C$425,000 (Concurrent Financing) (a total of up to 3,863,636 shares).
  • The forward-looking information and forward-looking statements contained herein may include, but is not limited to, statements regarding the acquisition of Nasalbinoid Natural Devices, the concurrent private placement, and the finders fee.

Akerna Flash Report: In Q1 2020 Women Outspent Men on Cannabis

Friday, April 3, 2020 - 6:46pm

Total cannabis sales increased in Q1 2020 by 16% over Q4 2019.

Key Points: 
  • Total cannabis sales increased in Q1 2020 by 16% over Q4 2019.
  • Repeat buyers are consistently spending much more per visit, with the size of womens shopping carts growing even more than men, said Aryeh Primus, vice president of analytics, Akerna.
  • In March, the average basket size for women hit an all time high above $105, while for men basket size was below that for March 2019.
  • Flash Report is a look at buying trends in the cannabis market as captured by Akernas MJ Freeway subsidiary.

Gabapentin Enacarbil Market Research Report 2020 - ResearchAndMarkets.com

Friday, April 3, 2020 - 1:43pm

The "Gabapentin enacarbil (CAS 478296-72-9) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gabapentin enacarbil (CAS 478296-72-9) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Gabapentin Enacarbil.
  • The Gabapentin enacarbil global market report key points:
    The first chapter introduces the product (composition, structure, hazards, storage, toxicological & ecological information, etc.).
  • The fifth chapter deals with Gabapentin Enacarbil market trends and forecast, distinguish Gabapentin Enacarbil manufacturers and suppliers.